Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 10, 2026, 2:06 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–19 of 19 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: CKM Clear all
Completed Phase 1 Interventional Results available

Chemokine Modulation Therapy and Standard Chemotherapy Before Surgery for the Treatment of Early Stage Triple Negative Breast Cancer

NCT04081389
View directory record Official record
Conditions
Anatomic Stage 0 Breast Cancer AJCC v8, Anatomic Stage I Breast Cancer AJCC v8, Anatomic Stage IA Breast Cancer AJCC v8, Anatomic Stage IB Breast Cancer AJCC v8, Anatomic Stage II Breast Cancer AJCC v8, Anatomic Stage IIA Breast Cancer AJCC v8, Anatomic Stage IIB Breast Cancer AJCC v8, Early-Stage Breast Carcinoma, Estrogen Receptor Negative, HER2/Neu Negative, Progesterone Receptor Negative, Prognostic Stage 0 Breast Cancer AJCC v8, Prognostic Stage I Breast Cancer AJCC v8, Prognostic Stage IA Breast Cancer AJCC v8, Prognostic Stage IB Breast Cancer AJCC v8, Prognostic Stage II Breast Cancer AJCC v8, Prognostic Stage IIA Breast Cancer AJCC v8, Prognostic Stage IIB Breast Cancer AJCC v8, Triple-Negative Breast Carcinoma
Interventions
Celecoxib, Cyclophosphamide, Doxorubicin, Doxorubicin Hydrochloride, Paclitaxel, Recombinant Interferon Alfa-2b, Rintatolimod
Drug · Biological
Lead sponsor
Roswell Park Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2023
U.S. locations
1
States / cities
Buffalo, New York
Source: ClinicalTrials.gov public record
Updated Sep 10, 2023 · Synced Sep 10, 2026, 2:06 AM EDT
Not yet recruiting Phase 3 Interventional

CKM For Safe Use of SGLT2i in Type 1 Diabetes

NCT07211802
View directory record Official record
Conditions
Type 1 Diabetes (T1D)
Interventions
Sotagliflozin Low Dose, Sotagliflozin High Dose, Dual Continuous Glucose and Ketone Monitor
Drug · Device
Lead sponsor
University of California, San Diego
Other
Eligibility
18 Years and older
Enrollment
52 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2030
U.S. locations
1
States / cities
La Jolla, California
Source: ClinicalTrials.gov public record
Updated Oct 7, 2025 · Synced Sep 10, 2026, 2:06 AM EDT
Not yet recruiting Not applicable Interventional Accepts healthy volunteers

Using a Personalized Decision Support Tool to Help People With Type 1 Diabetes Manage Exercise

NCT07226583
View directory record Official record
Conditions
Type 1 Diabetes Mellitus, Exercise Physiology
Interventions
Standard-of-Care Guidance (SoC), Usual Care (UC), netIOB & Exercise Toolkit (NEXT), Continuous Glucose Monitoring, Continuous Ketone Monitoring
Behavioral · Device
Lead sponsor
Stanford University
Other
Eligibility
18 Years to 60 Years
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2027
U.S. locations
1
States / cities
Palo Alto, California
Source: ClinicalTrials.gov public record
Updated Aug 11, 2026 · Synced Sep 10, 2026, 2:06 AM EDT
Terminated Phase 2 Interventional Results available

Polarized Dendritic Cell (aDC1) Based Treatment, Interferon Alpha-2, Rintatolimod, and Celecoxib for the Treatment of HLA-A2+ Refractory Melanoma

NCT04093323
View directory record Official record
Conditions
HLA-A2 Positive Cells Present, Refractory Melanoma
Interventions
Alpha-type-1 Polarized Dendritic Cells, Celecoxib, PD-1 Ligand Inhibitor, PD1 Inhibitor, Recombinant Interferon Alfa-2b, Rintatolimod
Biological · Drug
Lead sponsor
Roswell Park Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
1
States / cities
Buffalo, New York
Source: ClinicalTrials.gov public record
Updated Feb 24, 2026 · Synced Sep 10, 2026, 2:06 AM EDT
Recruiting No phase listed Observational

Healthy Living BEYOND Weight Study

NCT07075341
View directory record Official record
Conditions
Overweight or Obesity
Interventions
None - Observational study
Other
Lead sponsor
American Heart Association
Other
Eligibility
18 Years and older
Enrollment
1,000,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2060
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Aug 5, 2025 · Synced Sep 10, 2026, 2:06 AM EDT
Terminated Phase 1Phase 2 Interventional Results available

Rintatolimod, Celecoxib and Interferon Alpha 2b With Pembrolizumab For the Treatment of Patients With Metastatic or Unresectable Triple Negative Breast Cancer

NCT05756166
View directory record Official record
Conditions
Anatomic Stage IV Breast Cancer AJCC v8, Metastatic Triple-Negative Breast Carcinoma, Unresectable Triple-Negative Breast Carcinoma
Interventions
Biopsy, Biospecimen Collection, Celecoxib, Computed Tomography, Interferon Alpha-2, Magnetic Resonance Imaging, Pembrolizumab, Rintatolimod
Procedure · Drug · Biological
Lead sponsor
Roswell Park Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
1
States / cities
Buffalo, New York
Source: ClinicalTrials.gov public record
Updated Aug 30, 2026 · Synced Sep 10, 2026, 2:06 AM EDT
Recruiting Not applicable Interventional

Well-Formulated Ketogenic Diet Polycystic Kidney Disease

NCT06325644
View directory record Official record
Conditions
Polycystic Kidney Disease
Interventions
Ketogenic Diet, Ketone/Glucose Monitoring, CGM/CKM, Blood Draw, Body Composition, Change in glomerular filtration rate (mg/mmol) via magnetic resonance imaging (MRI) .
Other · Biological
Lead sponsor
Ohio State University
Other
Eligibility
18 Years to 65 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated May 13, 2026 · Synced Sep 10, 2026, 2:06 AM EDT
Active, not recruiting Not applicable Interventional Accepts healthy volunteers

Strategies to Augment Ketosis: Ketone Conferred Resiliency Against Sleep Restriction

NCT05519644
View directory record Official record
Conditions
Sleep Deprivation
Interventions
Sleep Deprivation, Heart Rate, Sleep Monitoring, Diet, Exercise Performance, Surveys, McGill Pain Questionnaire, Shortened Profile of Mood States, Pittsburg Sleep Index, Cognitive performance, Marksmanship Performance, Quick Board, Advanced Medical Technologies Inc, Jump Test, CGM/CKM, Blood Draw, Ketone Supplement
Other · Behavioral · Biological + 1 more
Lead sponsor
Ohio State University
Other
Eligibility
18 Years to 40 Years
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2026
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated May 31, 2026 · Synced Sep 10, 2026, 2:06 AM EDT
Active, not recruiting Not applicable Interventional Accepts healthy volunteers

Strategies to Augment Ketosis: Optimization of Ketone Delivery Strategies

NCT05501366
View directory record Official record
Conditions
Ketosis
Interventions
Ketone Supplement, Beverage Tolerability Questionnaire (BTQ) and satiety visual analogue scale, Blood Draw, Breath Reading, Heart Rate Variability, CGM/CKM, DXA, Urine Analysis
Dietary Supplement · Behavioral · Biological + 2 more
Lead sponsor
Ohio State University
Other
Eligibility
20 Years to 30 Years · Male only
Enrollment
14 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2027
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated May 28, 2026 · Synced Sep 10, 2026, 2:06 AM EDT
Recruiting Not applicable Interventional

Cardiovascular Kidney and Metabolic Health Assessment and Patient Empowerment

NCT07403669
View directory record Official record
Conditions
Acute MI, Heart Failure, Diabetes Mellitus, Kidney Disease
Interventions
CHAPERONE AI, CKMiq AI, Quality of Life
Other · Device
Lead sponsor
Aventyn, Inc.
Industry
Eligibility
18 Years and older
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
4
States / cities
Chandler, Arizona • Gilbert, Arizona • Phoenix, Arizona + 1 more
Source: ClinicalTrials.gov public record
Updated Feb 11, 2026 · Synced Sep 10, 2026, 2:06 AM EDT
Withdrawn Phase 1Phase 2 Interventional

Intensive Locoregional Chemoimmunotherapy for Recurrent Ovarian Cancer Plus Intranodal DC Vaccines

NCT02432378
View directory record Official record
Conditions
Cancer of Ovary, Cancer of the Ovary, Neoplasms, Ovarian, Ovarian Cancer, Ovary Cancer, Ovary Neoplasms
Interventions
Cisplatin + celecoxib + DC vaccine, Cisplatin + CKM + Celecoxib + DC Vaccine
Biological
Lead sponsor
Roswell Park Cancer Institute
Other
Eligibility
18 Years and older · Female only
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2025
U.S. locations
2
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jul 7, 2026 · Synced Sep 10, 2026, 2:06 AM EDT
Not yet recruiting Not applicable Interventional

RAndomized EHR-based Prescribing to Improve Disease-modifying Therapies for Cardio-Kidney-Metabolic Care (RAPID-CKM)

NCT07605390
View directory record Official record
Conditions
Chronic Kidney Disease, Type 2 Diabetes
Interventions
Epic-Based Clinician Notification, Usual Care
Other
Lead sponsor
Baylor Research Institute
Other
Eligibility
18 Years and older
Enrollment
600 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
2
States / cities
Dallas, Texas • Plano, Texas
Source: ClinicalTrials.gov public record
Updated Jul 19, 2026 · Synced Sep 10, 2026, 2:06 AM EDT
Withdrawn Phase 2 Interventional

A Study of Type-1 Polarized Dendritic Cell (αDC1) Vaccine in Combination With Tumor-Selective Chemokine Modulation (Interferon-α2b, Rintatolimod, and Celecoxib) in Subjects With Chemo-Refractory Metastatic Colorectal Cancer

NCT02615574
View directory record Official record
Conditions
Metastatic Colorectal Cancer
Interventions
αDC1 vaccine, CKM
Biological · Drug
Lead sponsor
Pawel Kalinski
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Sep 25, 2017 · Synced Sep 10, 2026, 2:06 AM EDT
Completed Phase 1Phase 2 Interventional Results available

αDC1 Vaccine + Chemokine Modulatory Regimen (CKM) as Adjuvant Treatment of Peritoneal Surface Malignancies

NCT02151448
View directory record Official record
Conditions
Malignant Neoplasm of Pancreas Metastatic to Peritoneal Surface, Malignant Peritoneal Mesothelioma, Peritoneal Carcinomatosis
Interventions
DC vaccine, Celecoxib, Interferon Alfa-2b, rintatolimod
Biological · Drug
Lead sponsor
David Bartlett
Other
Eligibility
18 Years and older
Enrollment
64 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2019
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jul 19, 2020 · Synced Sep 10, 2026, 2:06 AM EDT
Terminated Not applicable Interventional Accepts healthy volunteers

Testing Educational Videos on Conservative Kidney Management

NCT06577571
View directory record Official record
Conditions
Kidney Disease, Chronic
Interventions
CKM-EMPOWER
Other
Lead sponsor
University of Washington
Other
Eligibility
Not listed
Enrollment
4 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Jul 29, 2025 · Synced Sep 10, 2026, 2:06 AM EDT
Not listed Not applicable Interventional Accepts healthy volunteers

A Pilot Study of The CKM JumpStart Tool

NCT05753020
View directory record Official record
Conditions
Chronic Kidney Diseases
Interventions
CKM Jumpstart Tool
Behavioral
Lead sponsor
University of Washington
Other
Eligibility
75 Years and older
Enrollment
76 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2025
U.S. locations
2
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Aug 8, 2024 · Synced Sep 10, 2026, 2:06 AM EDT
Not yet recruiting Not applicable Interventional

Feasibility Study of a Continuous Glucose-Ketone Monitoring Device in People With Type 1 Diabetes

NCT06977633
View directory record Official record
Conditions
Type 1 Diabetes (T1D)
Interventions
Temporary Insulin Suspension, Glucose and ketone sensor
Behavioral · Device
Lead sponsor
Mahla Poudineh
Other
Eligibility
18 Years to 65 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
Palo Alto, California
Source: ClinicalTrials.gov public record
Updated May 4, 2026 · Synced Sep 10, 2026, 2:06 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Ketogenic Intervention in Depression

NCT06080932
View directory record Official record
Conditions
Depression, Ketosis
Interventions
Ketogenic Diet, NIH Toolbox, gradCPT, Resting-state fMRI, Task-fMRI, CGM/CKM, Blood Draw, Sleep Monitoring, Ketone/Glucose Monitoring, Body Composition, PHQ-9, WHO-5, SKID
Other · Biological · Behavioral
Lead sponsor
Ohio State University
Other
Eligibility
18 Years to 30 Years
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2024
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated May 28, 2025 · Synced Sep 10, 2026, 2:06 AM EDT
Completed Not applicable Interventional

Food is Medicine vs Lifestyle Medicine For Cardiovascular Kidney Metabolic (CKM) Syndrome

NCT06461273
View directory record Official record
Conditions
Diabetes Mellitus, Metabolic Syndrome, Obesity, Hypertension,Essential, Hyperlipidemias, Cardiovascular Diseases, Kidney Disease, Chronic
Interventions
Lifestyle Medicine Program, Medically Tailored Groceries
Behavioral
Lead sponsor
Rutgers, The State University of New Jersey
Other
Eligibility
18 Years to 75 Years
Enrollment
37 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
1
States / cities
Newark, New Jersey
Source: ClinicalTrials.gov public record
Updated Jul 8, 2026 · Synced Sep 10, 2026, 2:06 AM EDT